Sagar Lonial, MD, FACP

Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.

Nisha Joseph, MD leads an introduction to induction regimen options for patients with transplant-eligible NDMM.

Moderator Sagar Lonial, MD, FACP, and colleagues engage with the first patient case: a 65-year-old female diagnosed with transplant-eligible NDMM.

Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.

Expert perspectives on the advent of CAR T-cell therapy in relapsed/refractory multiple myeloma, and how its role may integrate with bispecific antibody therapy.

Before closing out their discussion on bispecific antibodies in relapsed/refractory multiple myeloma, key opinion leaders consider optimal sequencing of these agents.

A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.

Expert perspectives on recent clinical data on BCMA-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.

Patient and disease factors that help to select best first-line therapy in the setting of transplant-ineligible multiple myeloma.

Switching their focus to transplant-ineligible multiple myeloma, panelists review available triplet therapy regimens for induction therapy.

A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.

Concluding their discussion on newly diagnosed multiple myeloma, expert panelists consider treatment options for patients with high-risk disease.

Shared insight on the evolving treatment landscape of transplant-ineligible newly diagnosed multiple myeloma.

Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.

Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.

A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.